Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study (Q41745784)
Jump to navigation
Jump to search
scientific article published on 9 September 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study |
scientific article published on 9 September 2014 |
Statements
1 reference
Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study (English)
1 reference
Lawrence A Leiter
1 reference
Kun-Ho Yoon
1 reference
Pablo Arias
1 reference
Gisle Langslet
1 reference
John Xie
1 reference
Dainius A Balis
1 reference
Dawn Millington
1 reference
Frank Vercruysse
1 reference
William Canovatchel
1 reference
Gary Meininger
1 reference
9 September 2014
1 reference
1 reference
38
1 reference
3
1 reference
355-364
1 reference
Identifiers
1 reference
1 reference